Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CG2001 in Chinese Adult Males with Androgenetic Alopecia
NCT07038941Phase 1Completed
- Sponsor
- Beijing Dayspring Pharmaceutical Technology
- Start
- Mar 2024
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CG2001 in androgenetic alopecia (AGA) (7 arms), sponsored by Beijing Dayspring Pharmaceutical Technology. Primary endpoint: Safety and tolerability. Started Mar 2024; status: completed.
02
Drugs
CG2001
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT07038941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07038941.